Whalesbook
Ajanta Pharma delivered a strong fourth quarter for fiscal year 2026, with net profit rising 18.4% year-on-year to ₹266.7 crore. This result significantly exceeded analyst expectations, driven primarily by a substantial 56% jump in its United States generics revenue, which reached ₹505 crore. Overall revenue from operations grew by 21.5% to ₹1,421.64 crore, supported by a healthy EBITDA margin of 26.4%. The company's stock was trading between ₹2,800 and ₹2,900 in early May 2026, showing a modest 5.13% return over the past year, within a 52-week range of ₹2,329.90 to ₹3,228.00.
While growth in the U.S. market has been a key driver, its sustainability is a point of focus, especially as the Indian pharmaceutical sector faces slowing growth and price pressures in the U.S. Ajanta Pharma has also partnered with Biocon to market semaglutide, a drug for diabetes and weight management, across 26 countries in Africa, the Middle East, and Central Asia. This deal, expected to launch product commercially in late 2026 or early 2027, targets the growing market for these treatments. Analysts predict annual sales of $25-30 million by the second half of FY28, with the drug potentially generating significant profit margins. This diversification complements Ajanta Pharma's core business in branded generics, which made up 70% of FY26 revenue in markets like India, Asia, and Africa.
The company's valuation, with a trailing P/E ratio around 35-40x, is higher than peers like Cipla (approx. 23x) and Dr. Reddy's (approx. 19.4x), but in line with Sun Pharmaceutical Industries (approx. 35.6x). Ajanta Pharma has minimal debt (0.01 debt-to-equity ratio) and generates strong annual free cash flow, estimated at ₹8-10 billion. This financial health supports future investments. The Indian pharmaceutical sector itself is projected for steady growth, expected to reach USD 79.5 billion by 2033, boosted by local demand and exports.
However, potential challenges remain. The U.S. Food and Drug Administration (USFDA) inspected Ajanta Pharma's Paithan facility in April 2026, issuing a Form-483 with five observations. While the company plans to address these issues promptly, and a Form-483 is not a warning letter, such observations can point to compliance gaps that could affect future product approvals. Continued price erosion in the U.S. generics market poses a challenge to sustaining recent growth rates. While growth forecasts support Ajanta Pharma's valuation, it trades at a premium compared to some competitors, indicating high market expectations. Any failure to maintain its growth pace, especially with the new semaglutide product, could lead to a reassessment of its stock value.
Brokerage Prabhudas Lilladher maintains a 'BUY' rating, raising its target price to ₹3,400, based on a projected 30x FY28E earnings multiple. The firm forecasts 17% compound annual growth (CAGR) for EBITDA/PAT from FY26 to FY28E, with strong Return on Equity (RoE) and Return on Capital Employed (RoCE) expected. Overall analyst sentiment is positive, with 10 of 12 tracked analysts rating Ajanta Pharma a 'BUY', setting an average 12-month target price near ₹3,203. TipRanks also shows a 'Moderate Buy' consensus with an average target of ₹3,270. Ajanta Pharma's strong free cash flow is expected to fund ongoing investments and potential acquisitions, supporting its medium-term growth prospects.